TY - JOUR
T1 - Melatonin in children and adolescents with insomnia
T2 - A retrospective study
AU - Ivanenko, Anna
AU - Crabtree, Valerie Mc Laughlin
AU - Tauman, Riva
AU - Gozal, David
PY - 2003
Y1 - 2003
N2 - Effectiveness and tolerability of melatonin was assessed in 32 children (mean age 9.6 ± 4.5 years) with chronic sleep initiation and sleep maintenance problems treated naturalistically in a pediatric sleep medicine center. Children received melatonin for an average of 2.1 ± 2.0 months at a final average dose of 2.0 ± 1.2 mg administered 1 hour before bedtime. Twenty-nine (90.6%) children exhibited partial improvement to complete resolution of their sleep problems as measured by sleep latency time and number of awakenings reported by parents. Thus, melatonin may be effective, safe, and well tolerated in the treatment of chronic insomnia in children.
AB - Effectiveness and tolerability of melatonin was assessed in 32 children (mean age 9.6 ± 4.5 years) with chronic sleep initiation and sleep maintenance problems treated naturalistically in a pediatric sleep medicine center. Children received melatonin for an average of 2.1 ± 2.0 months at a final average dose of 2.0 ± 1.2 mg administered 1 hour before bedtime. Twenty-nine (90.6%) children exhibited partial improvement to complete resolution of their sleep problems as measured by sleep latency time and number of awakenings reported by parents. Thus, melatonin may be effective, safe, and well tolerated in the treatment of chronic insomnia in children.
UR - http://www.scopus.com/inward/record.url?scp=0037261133&partnerID=8YFLogxK
U2 - 10.1177/000992280304200108
DO - 10.1177/000992280304200108
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 12635982
AN - SCOPUS:0037261133
SN - 0009-9228
VL - 42
SP - 51
EP - 58
JO - Clinical Pediatrics
JF - Clinical Pediatrics
IS - 1
ER -